Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Nanoparticles-based Delivery of gene edIting Tools in hematopoietic Stem cells to treat Beta-hemoglobinopathies in vivo

Objective

Beta-hemoglobinopathies aBeta-hemoglobinopathies are the most common genetic diseases worldwide. Current gene therapies rely on ex vivo treatment of isolated hematopoietic stem cells (HSCs) with CRISPR/Cas9, followed by reinfusion in the patient. However, HSCs are highly sensitive to DNA double-strand breaks (DSBs) that can lead to apoptosis and generate large genomic rearrangements. Furthermore, current CRISPR/Cas9 therapeutic protocols involve complex HSC manipulations that reduce HSC fitness and can lead to cytotoxicity (e.g. because of the electroporation of the gene editing components). This is particularly true for HSCs from β-hemoglobinopathy patients, as they are more susceptible to electroporation-based gene editing procedures. In the ongoing DITSB ERC project, we developed efficacious and safe treatment strategies for β-hemoglobinopathies based on precise base editing (rather than DSB-induced DNA repair). However, toxicity due to the delivery method (i.e. electroporation) was still observed. In NDITSB, we will use lipid nanoparticles (LNPs) to deliver the editing components to human HSCs, with the goal of achieving a safe and reproducible transfection efficiency. Cutting-edge LNP formulations will be first screened in vitro in patients’ HSCs to select the safest and most efficacious particles that will be subsequently tested in an in vivo xenotransplantation model to demonstrate the targeting and correction of long-term HSCs. Importantly, we will evaluate the effect of LNPs in patients’ HSCs, as our studies highlighted disease-specific responses to gene editing. Therefore, the use of LNPs could represent an alternative and less toxic delivery system of the gene editing components. This work will pave the way for the development of an in vivo gene therapy strategy based on the intravenous injection of LNPs targeting HSCs in situ. This will simplify the gene therapy protocol and reduce the costs, thus allowing a widespread use of this therapeutic approach.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2026-POC

See all projects funded under this call

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 85 000,00
Address
RUE DE TOLBIAC 101
75654 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (2)